Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.
FAIL · Does not pass the screen
10.60 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price10.60 USD at the 6 Nov 2026 close
Our value readUndervalued vs our fair value, as of 6 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.06, read 2026-11-03
Ethical does not pass the values gate
Price10.60 USD
Fair value20.00
Ethical score70.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-30Read Markup7.44+42.5% to today ✓Distribution gives way to Markup after a 14% rise in 4 weeks
2026-10-02Read Distribution6.50+63.1% to today Accumulation gives way to Distribution after a 17% slide in 5 weeks
2026-08-27Read Accumulation7.87+34.7% to today ✓Distribution gives way to Accumulation after a 29% rise in 8 weeks
2026-07-02Read Distribution6.10+73.8% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Precision Biosciences Inc holds its Markup at $10.60. Consolidating, no directional conviction, held for 55 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 55 days
Price at the screen
$10.60
Valuation
N/A trailing · -4.16 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.25
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
18.66%
Below 33%
Interest-bearing debt is just 18.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.48%
Below 33%
Cash held in interest-bearing accounts and securities is 0.5% of assets, under the one-third limit.
Pass
Receivables
71.77%
Below 49%
Money owed to the company is 71.8% of assets, above the 49% limit.
Fail
Revenue purity
12.37%
Below 5%
12.4% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Precision Biosciences's business is fine, but its receivables are about 72% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DTIL's ethical verdict changes
Today DTIL does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 47% discount to our $20.00 fair value, none competitive moat, 37,272.40% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 47.0% discount to the base estimate.
Where our models see it going: fair-value estimate $20.00, with a range of $19.00 to $21.20, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it stands out
A 37272%-growth business trading at just -4.2x forward earnings, with a none competitive moat and minimal debt. That is a 47% discount to our $20.00 fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 5 analysts rate it Strong Buy with a $20.00 average target, about 89% above the screened price.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DTIL trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-06Markup$9.87+32.7%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 32.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 9% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $30. Insiders have been net buyers over the past quarter.
2026-10-30Markup · changed$7.44+22.0%Entry 9
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 22.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 9% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $30. Insiders have been net buyers over the past quarter.
2026-10-23Distribution$6.10+0.0%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $30. Insiders have been net buyers over the past quarter.
2026-10-16Distribution$6.10-6.2%Entry 7
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 15% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $30. Insiders have been net buyers over the past quarter.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 17.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 15% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $30. Insiders have been net buyers over the past quarter.
2026-08-27Accumulation · changed$7.87+0.0%Entry 5
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 15% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $30.
2026-07-27Distribution$7.87+29.0%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 29.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 15% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $30.
2026-07-18Distribution$6.10+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 15% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $30.
2026-07-03Distribution$6.10+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$6.10Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.